LAMEA myocardial infarction market is estimated to grow at the fastest CAGR of around 5.2% during the forecast period. The market is growing considerably owing to the increasing prevalence of hypertension and CVD. As per the study conducted by the Wits University scientists, South Africa has the largest prevalence of hypertension in the southern African region. The increasing prevalence of hypertension raises the possibility of a heart attack in the region. As per the data published by the Ministry of Health and Prevention (MOHAP), UAE, in September 2019, the prevalence of hypertension in the country has recorded 28.8%. This represents a significant number of hypertensive patients in the country. This rising hypertension among patients in South Africa and UAE is expected to boost the adoption of diagnosis and treatment procedures for myocardial infarction, to reduce the possibility of occurrence of severe conditions, including heart attack.
The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.
The companies which are contributing to the growth of the LAMEA myocardial infarction market include AstraZeneca PLC, Bayer AG, Abbott Laboratories Inc., GlaxoSmithKline PLC, Pfizer Inc., Koninklijke Philips N.V., Medtronic PLC, and Merck KGaA. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Research Methodology
The market study of the LAMEA myocardial infarction market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. LAMEA Myocardial Infarction Market by Type
5.1.1. Non-ST-elevation myocardial infarction (NSTEMI)
5.1.2. ST-elevation myocardial infarction (STEMI)
5.1.3. Silent Heart Attacks
5.2. LAMEA Myocardial Infarction Market by Device
5.2.1. Left Ventricular Assist Device (LVAD)
5.2.2. Pacemaker
5.2.3. Catheters
5.2.4. Implantable Cardioverter-Defibrillator (ICD)
5.2.5. Others (Stent Graft)
5.3. LAMEA Myocardial Infarction Market by Diagnosis
5.3.1. Electrocardiography (ECG)
5.3.2. Chest X-Ray
5.3.3. Computed Tomography (CT Scan)
5.3.4. Echocardiography
5.3.5. Others (Blood Test)
5.4. LAMEA Myocardial Infarction Market by Treatment
5.4.1. Medication
5.4.1.1. Analgesics
5.4.1.2. Thrombolytic
5.4.1.3. Antiplatelet Agents
5.4.1.4. Glycoprotein IIb/IIIa Inhibitors
5.4.1.5. Others (Beta-Adrenergic Blockers)
5.4.2. Surgery
5.4.2.1. Angioplasty
5.4.2.2. Bypass Surgery
5.4.2.3. Heart Transplant
5.5. LAMEA Myocardial Infarction Market by End-User
5.5.1. Hospital & Clinics
5.5.2. Ambulatory Surgical Centers
5.5.3. Research Institutes
6. Regional Analysis
6.1. Brazil
6.2. Argentina
6.3. UAE
6.4. Kenya
6.5. South Africa
6.6. Nigeria
6.7. Rest of LAMEA
7. Company Profiles
7.1. Abbott Laboratories Inc.
7.2. AstraZeneca PLC
7.3. Bayer AG
7.4. Boston Scientific Corp.
7.5. Bristol-Myers Squibb Co.
7.6. Eli Lilly and Co.
7.7. GlaxoSmithKline Plc
7.8. Johnson & Johnson Services, Inc.
7.9. Medtronic PLC
7.10. Merck KGaA
7.11. Mylan N.V.
7.12. Novartis AG
7.13. Pfizer Inc.
7.14. Siemens AG
1. LAMEA MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
2. LAMEA MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICE, 2019-2026 ($ MILLION)
3. LAMEA MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2019-2026 ($ MILLION)
4. LAMEA MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
5. LAMEA MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2019-2026 ($ MILLION)
6. LAMEA MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
1. LAMEA MYOCARDIAL INFARCTION MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
2. LAMEA MYOCARDIAL INFARCTION MARKET SHARE BY TYPE, 2019 VS 2026 (%)
3. LAMEA MYOCARDIAL INFARCTION MARKET SHARE BY DEVICE, 2019 VS 2026 (%)
4. LAMEA MYOCARDIAL INFARCTION MARKET SHARE BY DIAGNOSIS, 2019 VS 2026 (%)
5. LAMEA MYOCARDIAL INFARCTION MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
6. LAMEA MYOCARDIAL INFARCTION MARKET SHARE BY END-USERS, 2019 VS 2026 (%)
7. BRAZIL MYOCARDIAL INFARCTION MARKET SIZE, 2019-2026 ($ MILLION)
8. ARGENTINA MYOCARDIAL INFARCTION MARKET SIZE, 2019-2026 ($ MILLION)
9. UAE MYOCARDIAL INFARCTION MARKET SIZE, 2019-2026 ($ MILLION)
10. KENYA MYOCARDIAL INFARCTION MARKET SIZE, 2019-2026 ($ MILLION)
11. SOUTH AFRICA MYOCARDIAL INFARCTION MARKET SIZE, 2019-2026 ($ MILLION)
12. NIGERIA MYOCARDIAL INFARCTION MARKET SIZE, 2019-2026 ($ MILLION)
13. REST OF LAMEA MYOCARDIAL INFARCTION MARKET SIZE, 2019-2026 ($ MILLION)